Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C608326-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
C608326-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,334.90 | |
C608326-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $299.90 | |
C608326-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,001.90 | |
C608326-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $999.90 | |
C608326-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,529.90 |
Synonyms | Carotegrast|401904-75-4|Carotegrast [INN]|UNII-Y1HYC6SO3F|Y1HYC6SO3F|(2S)-2-(2,6-dichlorobenzamido)-3-(4-(6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2h)-yl)phenyl)propanoic acid|CHEMBL4592659|(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-( |
---|---|
Specifications & Purity | ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of integrin α4β1;Inhibitor of integrin α4β7;Inhibitor of integrin; alpha 4 subunit (antigen CD49D; alpha 4 subunit of VLA-4 receptor) |
Product Description |
Carotegrast is an α4 integrin receptor inhibitor with anti-inflammatories activities.发送消息记录备注 安排活动 2 正在关注中 0
|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-(dimethylamino)-1-methyl-2,4-dioxoquinazolin-3-yl]phenyl]propanoic acid |
---|---|
INCHI | InChI=1S/C27H24Cl2N4O5/c1-31(2)17-11-12-22-18(14-17)25(35)33(27(38)32(22)3)16-9-7-15(8-10-16)13-21(26(36)37)30-24(34)23-19(28)5-4-6-20(23)29/h4-12,14,21H,13H2,1-3H3,(H,30,34)(H,36,37)/t21-/m0/s1 |
InChi Key | YQKBOUPIOWUMTE-NRFANRHFSA-N |
Canonical SMILES | CN1C2=C(C=C(C=C2)N(C)C)C(=O)N(C1=O)C3=CC=C(C=C3)CC(C(=O)O)NC(=O)C4=C(C=CC=C4Cl)Cl |
Isomeric SMILES | CN1C2=C(C=C(C=C2)N(C)C)C(=O)N(C1=O)C3=CC=C(C=C3)C[C@@H](C(=O)O)NC(=O)C4=C(C=CC=C4Cl)Cl |
Alternate CAS | 401904-75-4 |
PubChem CID | 10120218 |
Molecular Weight | 555.41 |
PubChem CID | 10120218 |
---|---|
CAS Registry No. | 401904-75-4 |
Enter Lot Number to search for COA:
1. Sugiura T, Kageyama S, Andou A, Miyazawa T, Ejima C, Nakayama A, Dohi T, Eda H. (2013) Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice.. J Crohns Colitis, 7 (11): (e533-42). [PMID:23623333] |
2. Vetter M, Neurath MF. (2017) Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges.. Therap Adv Gastroenterol, 10 (10): (773-790). [PMID:29051788] |
3. White JR, Phillips F, Monaghan T, Fateen W, Samuel S, Ghosh S, Moran GW. (2018) Review article: novel oral-targeted therapies in inflammatory bowel disease.. Aliment Pharmacol Ther, 47 (12): (1610-1622). [PMID:29672874] |
4. Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. (2020) AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.. Br J Clin Pharmacol, 86 (3): (591-600). [PMID:31658381] |
5. Shukla T, Sands BE. (2019) Novel Non-biologic Targets for Inflammatory Bowel Disease.. Curr Gastroenterol Rep, 21 (5): (22). [PMID:31016396] |